Drug intelligence / Profile preview

AC0010 + nimotuzumab

Development stage: Preclinical
Lead developer: Accutar Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

This combination involves **AC0010 (Abivertinib)**, a third-generation irreversible EGFR tyrosine kinase inhibitor, and **Nimotuzumab**, a humanized monoclonal antibody targeting EGFR. AC0010 is effective against EGFR mutations, including T790M, and is used in non-small cell lung cancer (NSCLC). Nimotuzumab inhibits EGFR signaling and is used in various cancers like glioma and head and neck cancer. The combination aims to enhance antitumor effects by targeting EGFR through different mechanisms.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on AC0010 + nimotuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC0010 + nimotuzumab.

Explore the full profile